Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

By J. Kochenderfer, W. Wilson, J. Janik, M. Dudley, M. Stetler-Stevenson, S. Feldman, I. Maric, M. Raffeld, Debbie-Ann N. Nathan, B. Lanier and 2 more. Blood, 2010

1,314 citations recorded by the source corpus.

Subfields: Biomedical Engineering, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/3fe81d0ce29742ba94296e7e02fa52a791a79a4c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomedical Engineering

1. S. Rosenberg
2. J. Kochenderfer
3. R. Brentjens

In Molecular Biology

1. C. June
2. S. Rosenberg
3. Wendell A. Lim
4. Michel Sadelain

In Oncology

1. J. Kochenderfer
2. Michel Sadelain
3. C. June
4. R. Brentjens
5. Wendell A. Lim
6. Kathryn M. Cappell
7. S. Rosenberg
8. I. Rivière

Citations in the corpus

• IL-2: The First Effective Immunotherapy for Human Cancer (2014, background): “The first report of ACT using a CAR targeting CD19 to mediate regression of CD19-expressing lymphomas in humans was published in 2010 (81).”
• Gene therapy comes of age (2018, neutral): “CAR-T cells have had a large impact on the treatment of certain cancers (139), and this success provides a foundation for future T cell–based therapies for other cancers and other diseases such as autoimmune disorders and AIDS (5, 140).”
• CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia (2013, background): “MSK-ALL04 59 t(9;11), 9p21 deletion ECOG2993 (24) 5 weeks Vinc/Pred Refractory disease, 63% blasts in BM MRD Y Ineligible for Allo-SCT, relapse 90 days”
• Toxicities of chimeric antigen receptor T cells: recognition and management. (2016, neutral): “Prolonged B-cell aplasia is an expected and common toxicity of anti-CD19 CAR T cells.(5,6,8-16,31,54) B-cell aplasia and hypogammaglobulinemia may last 2 months to over 2 years following CAR T-cell infusion.”
• Cancer immunotherapy: harnessing the immune system to battle cancer. (2015, result): “In 2010, a case report showed an encouraging result using CD19 CAR T cells for treating a patient with lymphoma (25).”
• Long-term outcomes following CAR T cell therapy: what we know so far (2023, background): “(2022)(23) Axicabtagene ciloleucel, multicentre phase III DLBCL (126); HGBCL (31); NR (18); other (5) 25 months ORR: 83%; CRR: 65% Median PFS: 15 months Median DOR: 27 months”
• CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. (2011, background): “CD19-28ζ+ T cells and thus their clinical benefits (8, 20, 21).”